Digital RDD 2020 Poster: Development of an X-ray Diffraction Method for the Quantification of API Recrystallized API

Request a copy of our poster, 'Development of an X-ray Diffraction Method for the Quantification of API Recrystallized API.' Typically, in developing dry powder inhaler (DPI) formulations, a stable crystalline form of the active pharmaceutical ingredient (API) is desired. However, often to produce crystalline particles of suitable size for inhalation, micronization processes will be required, resulting in surface amorphous material which may affect the efficacy of the product. If required, additional conditioning/processing steps may then be applied to the API (or to ensure drug product stability under use) without requiring any additional solid-state characterization of the API in the drug product.